Iovance Biotherapeutics shares are trading lower after Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $19 to $10.
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics shares are trading lower after Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $19 to $10.
July 29, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Iovance Biotherapeutics shares are trading lower after Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $19 to $10.
The downgrade from Overweight to Neutral and the significant reduction in the price target from $19 to $10 by Piper Sandler is likely to negatively impact investor sentiment and lead to a short-term decline in Iovance Biotherapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100